Goldman Sachs Group Inc Connect Biopharma Holdings LTD Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.8 - $1.65 $4,764 - $9,827	-5,956 Reduced 30.62%	13,497 $17,000
Q3 2022 Nov 10, 2022	SELL	$0.8 - $1.65 $4,764 - $9,827	-5,956 Reduced 30.62%	13,497 $0
Q2 2022 May 14, 2024	BUY	$0.56 - $3.25 $10,893 - $63,222	19,453 New	19,453 $17,000
Q2 2022 Aug 15, 2022	BUY	$0.56 - $3.25 $96 - $559	172 Added 0.89%	19,453 $17,000
Q1 2022 May 16, 2022	BUY	$2.46 - $5.92 $18,425 - $44,340	7,490 Added 63.52%	19,281 $58,000
Q4 2021 Feb 14, 2022	BUY	$4.26 - $23.33 $50,229 - $275,084	11,791 New	11,791 $61,000

3.05M

Ticker CNTB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,015,800
Market Cap $55M
Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for t...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.